

Accepted Manuscript

Title: Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution

Authors: J. Raphael MD G. Le Teuff PhD A. Hollebecque MD C. Massard MD R. Bahleda MD J. Margery MD B. Besse MD, PhD J.-C. Soria MD, PhD D. Planchard MD, PhD



PII: S0169-5002(14)00215-3
DOI: <http://dx.doi.org/doi:10.1016/j.lungcan.2014.05.006>
Reference: LUNG 4603

To appear in: *Lung Cancer*

Received date: 10-2-2014
Revised date: 3-5-2014
Accepted date: 7-5-2014

Please cite this article as: RAPHAEL J, TEUFF GLE, HOLLEBECQUE A, MASSARD C, BAHLEDA R, MARGERY J, BESSE B, SORIA J-C, PLANCHARD D, Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution, *Lung Cancer* (2014), <http://dx.doi.org/10.1016/j.lungcan.2014.05.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Twenty different phase 1 trial enrolling 45 mesothelioma patients were described
- Results show mostly stable disease and an acceptable toxicity profile
- The most promising class identified was the Cellular Motility inhibitors class
- A better patient selection and response evaluation is needed
- Enrolling mesothelioma patients in clinical trials of all phases is crucial

Download English Version:

<https://daneshyari.com/en/article/10910926>

Download Persian Version:

<https://daneshyari.com/article/10910926>

[Daneshyari.com](https://daneshyari.com)